Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Exhaled nitric oxide and COPD

D.R. Taylor, J. Dummer
European Respiratory Journal 2010 36: 692; DOI: 10.1183/09031936.00058310
D.R. Taylor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: robin.taylor@stonebow.otago.ac.nz
J. Dummer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

We were interested to read the paper by Lehtimäki et al. 1 recently published in the European Respiratory Journal, in which those authors reported that “high pre-treatment levels of J′aw,NO [bronchial nitric oxide flux] are related to symptom relief and improvement of airway obstruction” when inhaled fluticasone is given to patients with chronic obstructive pulmonary disease (COPD). Their data complement those which we ourselves have recently published 2.

In their cohort of patients, only five (12.5%) out of 40 demonstrated an objective improvement in airway calibre following inhaled fluticasone (change in forced expiratory volume in 1 s of ≥12% and/or ≥200 mL), a proportion that is similar to that reported in most other studies. Somewhat surprisingly, the number of patients who show symptomatic improvement with inhaled steroid was higher (50% had a change in St George's Respiratory Questionnaire of ≥4), but this may have been influenced by the fact that the study was not blinded. Overall, these changes were associated with small but statistically significant reductions in both J′aw,NO and the fraction of exhaled nitric oxide (FeNO) at a flow rate of 50 mL·s−1.

In COPD, it is critical to know the extent to which a biomarker may be used to predict the response to treatment, particularly given that response rates to inhaled steroids are so low. In our study, using receiver operating curve analyses, we found FeNO to be only a weak predictor of steroid response, with a positive predictive value of 67% at a cut-off point of 50 ppb. More importantly, the negative predictive value was high (82%), implying that FeNO measurements can be used to predict when a response to treatment is unlikely 2.

It is important for Lehtimäki et al. 1 to provide similar information from their own dataset. At present, their conclusions are open-ended and leave the reader with doubts as to whether the relationship between exhaled nitric oxide and the response to inhaled steroid in COPD has any clinical utility. The publication of additional data would help to clarify this issue.

Footnotes

  • Statement of Interest

    A statement of interest for D.R. Taylor can be found at www.erj.ersjournals.com/misc/statements.dtl

    • ©2010 ERS

    REFERENCES

    1. ↵
      1. Lehtimäki L,
      2. Kankaanranta H,
      3. Saarelainen S,
      4. et al
      . Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur Respir J 2010; 35: 72–78.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Dummer JF,
      2. Epton MJ,
      3. Cowan JO,
      4. et al
      . Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med 2009; 180: 846–852.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 36 Issue 3 Table of Contents
    European Respiratory Journal: 36 (3)
    • Table of Contents
    • Table of Contents (PDF)
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Exhaled nitric oxide and COPD
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Exhaled nitric oxide and COPD
    D.R. Taylor, J. Dummer
    European Respiratory Journal Sep 2010, 36 (3) 692; DOI: 10.1183/09031936.00058310

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Exhaled nitric oxide and COPD
    D.R. Taylor, J. Dummer
    European Respiratory Journal Sep 2010, 36 (3) 692; DOI: 10.1183/09031936.00058310
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Footnotes
      • REFERENCES
    • Info & Metrics
    • PDF

    Subjects

    • COPD and smoking
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Fixed breathing protocols in multiple-breath washout testing in children
    • Fixed breathing protocols in multiple-breath washout testing in children
    • Connexins and the pulmonary vascular response to hypoxia
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • CME
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2021 by the European Respiratory Society